<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">07-PONE-RA-01036R2</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0001765</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Diabetes and Endocrinology</subject><subject>Cell Biology/Gene Expression</subject><subject>Physiology/Endocrinology</subject><subject>Physiology/Integrative Physiology</subject><subject>Diabetes and Endocrinology/Obesity</subject><subject>Diabetes and Endocrinology/Type 2 Diabetes</subject></subj-group></article-categories><title-group><article-title>Fetuin-A Induces Cytokine Expression and Suppresses Adiponectin Production</article-title><alt-title alt-title-type="running-head">Fetuin-A and Adiponectin</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hennige</surname><given-names>Anita M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Staiger</surname><given-names>Harald</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wicke</surname><given-names>Corinna</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Machicao</surname><given-names>Fausto</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fritsche</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>H&#x000e4;ring</surname><given-names>Hans-Ulrich</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Stefan</surname><given-names>Norbert</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Internal Medicine, Division of Endocrinology, Nephrology, Vascular Disease and Clinical Chemistry, University of T&#x000fc;bingen, T&#x000fc;bingen, Germany</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of General, Visceral and Transplantation Surgery, University of T&#x000fc;bingen, T&#x000fc;bingen, Germany</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Bartolomucci</surname><given-names>Alessandro</given-names></name><role>Academic Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Parma, Italy</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>norbert.stefan@med.uni-tuebingen.de</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: HH HS FM NS AF AH CW. Performed the experiments: HS NS AH. Analyzed the data: HS NS AF AH. Contributed reagents/materials/analysis tools: HS FM NS AH CW. Wrote the paper: HH HS NS AH.</p></fn></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>12</day><month>3</month><year>2008</year></pub-date><volume>3</volume><issue>3</issue><elocation-id>e1765</elocation-id><history><date date-type="received"><day>4</day><month>4</month><year>2007</year></date><date date-type="accepted"><day>6</day><month>2</month><year>2008</year></date></history><copyright-statement>Hennige et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title>Background</title><p>The secreted liver protein fetuin-A (AHSG) is up-regulated in hepatic steatosis and the metabolic syndrome. These states are strongly associated with low-grade inflammation and hypoadiponectinemia. We, therefore, hypothesized that fetuin-A may play a role in the regulation of cytokine expression, the modulation of adipose tissue expression and plasma concentration of the insulin-sensitizing and atheroprotective adipokine adiponectin.</p></sec><sec><title>Methodology and Principal Findings</title><p>Human monocytic THP1 cells and human <italic>in vitro</italic> differenttiated adipocytes as well as C57BL/6 mice were treated with fetuin-A. mRNA expression of the genes encoding inflammatory cytokines and the adipokine adiponectin (ADIPOQ) was assessed by real-time RT-PCR. In 122 subjects, plasma levels of fetuin-A, adiponectin and, in a subgroup, the multimeric forms of adiponectin were determined. Fetuin-A treatment induced <italic>TNF</italic> and <italic>IL1B</italic> mRNA expression in THP1 cells (p&#x0003c;0.05). Treatment of mice with fetuin-A, analogously, resulted in a marked increase in adipose tissue <italic>Tnf</italic> mRNA as well as <italic>Il6</italic> expression (27- and 174-fold, respectively). These effects were accompanied by a decrease in adipose tissue <italic>Adipoq</italic> mRNA expression and lower circulating adiponectin levels (p&#x0003c;0.05, both). Furthermore, fetuin-A repressed <italic>ADIPOQ</italic> mRNA expression of human <italic>in vitro</italic> differentiated adipocytes (p&#x0003c;0.02) and induced inflammatory cytokine expression. In humans in plasma, fetuin-A correlated positively with high-sensitivity C-reactive protein, a marker of subclinical inflammation (r&#x0200a;&#x0003d;&#x0200a;0.26, p&#x0200a;&#x0003d;&#x0200a;0.01), and negatively with total- (r&#x0200a;&#x0003d;&#x0200a;&#x02212;0.28, p&#x0200a;&#x0003d;&#x0200a;0.02) and, particularly, high molecular weight adiponectin (r&#x0200a;&#x0003d;&#x0200a;&#x02212;0.36, p&#x0200a;&#x0003d;&#x0200a;0.01).</p></sec><sec><title>Conclusions and Significance</title><p>We provide novel evidence that the secreted liver protein fetuin-A induces low-grade inflammation and represses adiponectin production in animals and in humans. These data suggest an important role of fatty liver in the pathophysiology of insulin resistance and atherosclerosis.</p></sec></abstract><counts><page-count count="9"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Fetuin-A (former name for the human protein: &#x003b1;<sub>2</sub>-Heremans-Schmid glycoprotein, AHSG) is an abundant serum protein <xref ref-type="bibr" rid="pone.0001765-Dziegielewska1">&#x0005b;1&#x0005d;</xref> that is exclusively produced by the liver, tongue, and placenta <xref ref-type="bibr" rid="pone.0001765-Denecke1">&#x0005b;2&#x0005d;</xref>. In several studies, fetuin-A was shown to act as a natural inhibitor of the insulin receptor tyrosine kinase in liver and skeletal muscle <xref ref-type="bibr" rid="pone.0001765-Auberger1">&#x0005b;3&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001765-Mathews2">&#x0005b;7&#x0005d;</xref>. In addition, mice deficient for the gene encoding fetuin-A displayed improved insulin sensitivity and were resistant to weight gain upon a high-fat diet <xref ref-type="bibr" rid="pone.0001765-Mathews3">&#x0005b;8&#x0005d;</xref>. Besides these well-documented effects of fetuin-A on the insulin receptor of muscle and liver, another mechanism of this protein may include effects on adipose tissue to induce whole-body insulin resistance. Recently, polymorphisms in the gene encoding human fetuin-A were found to be not only associated with type 2 diabetes <xref ref-type="bibr" rid="pone.0001765-Siddiq1">&#x0005b;9&#x0005d;</xref>, but also to affect insulin action in adipocytes <xref ref-type="bibr" rid="pone.0001765-Dahlman1">&#x0005b;10&#x0005d;</xref>. Furthermore, fetuin-A was shown to exert direct pro-adipogenic properties <xref ref-type="bibr" rid="pone.0001765-Schmidt1">&#x0005b;11&#x0005d;</xref>, however, the underlying mechanisms are unknown.</p><p>The genes encoding human fetuin-A (<italic>AHSG</italic>) and human adiponectin (<italic>ADIPOQ</italic>), which is almost exclusively secreted from adipose tissue and represents an important determinant of whole-body insulin sensitivity <xref ref-type="bibr" rid="pone.0001765-Kadowaki1">&#x0005b;12&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001765-Bacha1">&#x0005b;16&#x0005d;</xref> and cardiovascular disease <xref ref-type="bibr" rid="pone.0001765-Pischon1">&#x0005b;17&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001765-Rothenbacher1">&#x0005b;20&#x0005d;</xref>, are located next to each other on chromosome 3q27. This chromosomal region was previously mapped as a type 2 diabetes and metabolic syndrome susceptibility locus <xref ref-type="bibr" rid="pone.0001765-Vionnet1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001765-Kissebah1">&#x0005b;22&#x0005d;</xref>, and also shows close linkage to variation in plasma adiponectin levels <xref ref-type="bibr" rid="pone.0001765-Pollin1">&#x0005b;23&#x0005d;</xref>. However, not all of the variability in plasma adiponectin levels can be explained by genetic variation of the <italic>ADIPOQ</italic> gene <xref ref-type="bibr" rid="pone.0001765-Pollin1">&#x0005b;23&#x0005d;</xref>. Therefore, other genes under this linkage peak may encode proteins regulating adiponectin production with <italic>AHSG</italic> representing a major candidate.</p><p>Recently, we and others have shown that human plasma fetuin-A levels are correlated with fatty liver, impaired glucose tolerance, and insulin resistance <xref ref-type="bibr" rid="pone.0001765-Stefan2">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001765-Mori1">&#x0005b;25&#x0005d;</xref>. Moreover, a recent study provided evidence that human plasma fetuin-A levels are strongly associated with the metabolic syndrome and an atherogenic lipid profile <xref ref-type="bibr" rid="pone.0001765-Ix1">&#x0005b;26&#x0005d;</xref>. Since these states are characterized by subclinical inflammation and hypoadiponectinemia <xref ref-type="bibr" rid="pone.0001765-Trujillo1">&#x0005b;27&#x0005d;</xref>, and based on the chromosomal localization of <italic>AHSG</italic>, we investigated whether fetuin-A regulates cytokine expression, modulates adipose tissue expression and the plasma concentration of the insulin-sensitizing and atheroprotective adipokine adiponectin.</p></sec><sec sec-type="materials|methods" id="s2"><title>Material and Methods</title><sec id="s2a"><title>Cell culture</title><p>Human THP1 monocytes were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in IMDM supplemented with 10&#x00025; (v/v) FCS, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, and 2 mmol/l glutamine. Cells were left untreated or stimulated for 8 and 24 h with 600 &#x000b5;g/ml human fetuin-A (purity &#x02265;95&#x00025;, Sigma-Aldrich, Steinheim, Germany), a high physiological dose, or human serum albumin for control (ZLB Behring, Marburg, Germany), respectively.</p><p>Human preadipocytes were isolated from abdominal subcutaneous fat biopsies as previously described <xref ref-type="bibr" rid="pone.0001765-Schling1">&#x0005b;28&#x0005d;</xref>. The donors underwent abdominal surgery for clinical purposes and gave informed written consent to the study. Isolated preadipocytes were expanded in &#x003b1;-MEM/Ham's nutrient mixture F12 (1:1) containing 20&#x00025; (v/v) FCS, 1&#x00025; (v/v) chicken embryo extract (Sera Laboratories International, Horsted Keynes, UK), 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 0.5 &#x000b5;g/ml fungizone, and 2 mmol/l glutamine. First-pass cells were used for the experiments. At confluence, adipose conversion was induced by shifting the cells into DMEM/Ham's nutrient mixture F12 (1:1), 5&#x00025; (v/v) FCS, 17 &#x000b5;mol/l pantothenate, 1 &#x000b5;mol/l biotin, 2 &#x000b5;g/ml apo-transferrin, 1 &#x000b5;mol/l insulin, 100 IU/ml penicillin, 0.1 mg/ml streptomycin, 0.5 &#x000b5;g/ml fungizone, and 2 mmol/l glutamine (differentiation medium) supplemented with 0.5 mmol/l 3-isobutyl-1-methyl-xanthine, 1 &#x000b5;mol/l cortisol, 10 &#x000b5;mol/l troglitazone, and 50 &#x000b5;mol/l indomethacin for 7 days. Finally, the cells were allowed to terminally differentiate for another 7 days in differentiation medium without supplements. Medium was changed three times a week. In vitro differentiated adipocytes were washed once with PBS and pretreated overnight with insulin- and FCS-free differentiation medium. Thereafter, cells were incubated for 24 h with or without 300 &#x000b5;g/ml human or bovine fetuin-A, respectively, in insulin- and FCS-free differentiation medium prior to RNA isolation. The procedures were approved by the Ethical Committee of the T&#x000fc;bingen University Medical Department.</p></sec><sec id="s2b"><title>Animal studies</title><p>Male C57BL/6 mice were obtained from Charles River Laboratories (Sulzfeld, Germany). For in vivo stimulation, 12-week-old C57BL/6 mice kept on a regular diet obtained an intraperitoneal bolus of bovine fetuin-A (fetuin-I, Pedersen's preparation, purity &#x0223c;75&#x00025;, 0.75 mg/g body weight, ICN, Eschwege, Germany), human fetuin-A (0.5 mg/g body weight), or human serum albumin (0.5 mg/g body weight), respectively. Controls received a comparable amount of diluent (n &#x02265; 3 each). Serum and perigonadal adipose tissue were removed after 8 h. Tissue samples were stored at 4&#x000b0;C in RNAlater (Ambion, Huntingdon, United Kingdom). All procedures were conducted according to the guidelines of laboratory animal care and were approved by the local governmental commission for animal research. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR) and calculated as insulin (&#x000b5;U/ml) &#x000b7; glucose (mM)/22.5 <xref ref-type="bibr" rid="pone.0001765-Matthews1">&#x0005b;29&#x0005d;</xref>.</p></sec><sec id="s2c"><title>Real-time RT-PCR</title><p>For quantification of mRNA expression in mouse adipose tissue, RNA was isolated with peqGOLD TriFast according to the manufacturer's instructions (Peqlab, Erlangen, Germany). For quantification of THP1 monocyte and human adipocyte mRNA, cells were washed, harvested, and RNA was isolated with RNeasy silica-gel columns according to the manufacturer's instructions (Qiagen, Hilden, Germany). The total RNA was treated with RNase-free DNase I and transcribed into cDNA using AMV reverse transcriptase and the first strand cDNA kit from Roche Diagnostics (Mannheim, Germany). Quantitative PCR was performed with SYBR Green I dye on a high speed thermal cycler with integrated microvolume fluorometer according to the instructions of the manufacturer (Roche Diagnostics, Mannheim, Germany). Primers were obtained from Invitrogen (Karlsruhe, Germany) and PCR conditions are given in <xref ref-type="table" rid="pone-0001765-t001">Table 1</xref>. Measurements were performed in triplicate. Cellular mRNA contents are given, after correction for 28S-rRNA, in relative arbitrary units (RAU or &#x00025; of control).</p><table-wrap id="pone-0001765-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001765.t001</object-id><label>Table 1</label><caption><title>Conditions for RT-PCR quantification of specific mRNAs and 28S-rRNA.</title></caption><graphic id="pone-0001765-t001-1" xlink:href="pone.0001765.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001765-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">RNA</td><td align="left" rowspan="1" colspan="1">Forward primer (5&#x02032;&#x02192;3&#x02032;)</td><td align="left" rowspan="1" colspan="1">Reverse primer (5&#x02032;&#x02192;3&#x02032;)</td><td align="left" rowspan="1" colspan="1">T<sub>annealing</sub> (&#x000b0;C)</td><td align="left" rowspan="1" colspan="1">No. of cycles</td><td align="left" rowspan="1" colspan="1">MgCl<sub>2</sub> (mM)</td></tr></thead><tbody><tr><td colspan="6" align="left" rowspan="1"><bold>Murine</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Adipoq</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGTGAGACAGGAGATGTTGG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCTGATACTGGTCGTAGG TG</named-content></td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Lep</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACATTTCACACACGCAGTCG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGC ATT CAG GGC TAA CAT CC</named-content></td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">55</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Il6</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GATGCTACCAAACTGGATATAATC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGTCCTTAGCCACTCCTTCTGTG</named-content></td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Tnf</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AAATGGCCTCCCTCTCATCA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGATAGCAAATCGGCTGACG</named-content></td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Rbp4</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTTTTCTCGTGACCCCAATG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGAGGTGGGGGAAACTAAAC</named-content></td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">28S-rRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCAGTACTTCACTCCTGTCT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TCTAAGAGTGAGCAACGACG</named-content></td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td colspan="6" align="left" rowspan="1"><bold>Human</bold></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>ADIPOQ</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GTGATGGCAGAGATGGCAC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">AGAGGCTGACCTTCACATCC</named-content></td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>IL6</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CCAGCTATGAACTCCTTCTC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCTTGTTCCTCACATCTCTC</named-content></td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TNF</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCGTGGAGCTGAGAGATAAC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GATGTTCGTCCTCCTCACAG</named-content></td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>IL1B</italic> mRNA<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CATGGACAAGCTGAGGAAGA</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TTCAACACGCAGGACAGGTA</named-content></td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">45</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>PBEF1</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TCCAGGAAGCCAAAGATGTC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GGCCACTGTGATTGGATACC</named-content></td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>RETN</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCCGGATTTGGTTAGCTGAG</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTCATTGATGGCTTCTTCCA</named-content></td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CCL2</italic> mRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">GCCTCCAGCATGAAAGTCTC</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">TGGAATCCTGAACCCACTTC</named-content></td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">28S-rRNA</td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">ACG GCG GGA GTA ACT ATG ACT</named-content></td><td align="left" rowspan="1" colspan="1"><named-content content-type="gene">CTT GGC TGT GGT TTC GCT</named-content></td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">50</td><td align="left" rowspan="1" colspan="1">4</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>For detection of <italic>IL1B</italic> mRNA, the fluorescent dye-linked probes <named-content content-type="gene">5&#x02032;-AGGTGCTCAGGTCATTCTCCTGG-FL-3&#x02032;</named-content> and <named-content content-type="gene">5&#x02032;-Red640-AGGTCTGTGGGCAGGGAACC-PH-3&#x02032;</named-content> were used instead of SYBR Green.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2d"><title>Human subjects</title><p>A total of 122 individuals were studied. These subjects were at increased risk for type 2 diabetes and participated in an ongoing study <xref ref-type="bibr" rid="pone.0001765-Stefan2">&#x0005b;24&#x0005d;</xref>. Individuals were recruited from the southern part of Germany and were not related to each other. The participants did not take any medication known to affect glucose tolerance or insulin sensitivity. Informed written consent was obtained from all participants, and the Ethical Committee of the T&#x000fc;bingen University Medical Department had approved the protocol.</p></sec><sec id="s2e"><title>Hyperinsulinemic euglycemic clamp</title><p>Insulin sensitivity was determined in 49 human subjects as previously described <xref ref-type="bibr" rid="pone.0001765-Stefan2">&#x0005b;24&#x0005d;</xref>. In brief, subjects received a primed insulin infusion at a rate of 40 mU&#x000b7;m<sup>&#x02212;2</sup>&#x000b7;min<sup>&#x02212;1</sup> for 2 h. Plasma was drawn every 5 min for determination of plasma glucose, and glucose infusion was adjusted appropriately to maintain the fasting glucose level. An insulin sensitivity index for systemic glucose uptake (ISI; in &#x000b5;mol kg<sup>&#x02212;1</sup> min<sup>&#x02212;1</sup> pM<sup>&#x02212;1</sup>) was calculated as the mean infusion rate of glucose (in mol kg<sup>&#x02212;1</sup> min<sup>&#x02212;1</sup>) necessary to maintain euglycemia during the last 40 min of the hyperinsulinemic euglycemic clamp divided by the steady state plasma insulin concentration. The latter was the mean insulin concentration at min 100, 110, and 120 of the clamp (522&#x000b1;19 pM).</p></sec><sec id="s2f"><title>Other analytical procedures</title><p>Plasma glucose was determined using a bedside glucose analyzer (glucose oxidase method; Yellow Springs Instruments, Yellow Springs, CO, USA). Plasma insulin was determined by an enzyme immunoassay (Abbott Laboratories, Tokyo, Japan). Serum adiponectin levels in mice and fasting plasma fetuin-A levels in human subjects were measured using commercial enzyme-linked immunosorbent assays (ELISA, BioVendor Laboratory Medicine, Brno, Czech Republic). ELISAs were also used to measure serum concentrations of TNF-&#x003b1;, IL-6, and high sensitivity C-reactive protein (hsCRP, R&#x00026;D Systems Inc., MN, USA). Fasting plasma adiponectin levels in humans were determined by radioimmunoassay (LINCO Research, St. Charles, MO, USA). Multimeric forms of adiponectin were quantified using an enzyme immunoassay (ALPCO Diagnostics, Salem, NH, USA). Percentage of body fat was assessed by bioelectrical impedance.</p></sec><sec id="s2g"><title>Statistical analyses</title><p>Data are given as means&#x000b1;SEM. For 3-group comparisons, data were analyzed by ANOVA followed by Dunnett's test. Statistical comparison between treatment and control group were performed with the Student's t-test. To adjust for the effects of relevant covariates (age, gender, body fat) in the in vivo data, multivariate linear regression analysis was performed using log-transformed data. A p-value &#x0003c;0.05 was considered statistically significant. The statistical software package JMP 4.0 (SAS Institute Inc, Cary, NC, USA) was used.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Effect of fetuin-A on cytokine mRNA expression of human THP1 monocytes</title><p>Human THP1 monocytes were treated with human fetuin-A and, to evaluate the specificity of fetuin-A's effect and as control for general trophic effects, additionally with human albumin (600 &#x000b5;g/ml, each) for 8 h. Human fetuin-A induced the mRNA expression of <italic>TNF</italic> (ANOVA, F(14,12)&#x0200a;&#x0003d;&#x0200a;9.07, p&#x0200a;&#x0003d;&#x0200a;0.004, <xref ref-type="fig" rid="pone-0001765-g001">Figure 1A</xref>) and <italic>IL1B</italic> (ANOVA, F(14,12)&#x0200a;&#x0003d;&#x0200a;4.27, p&#x0200a;&#x0003d;&#x0200a;0.075, <xref ref-type="fig" rid="pone-0001765-g001">Figure 1B</xref>), but did not modulate mRNA expression of <italic>PBEF1</italic> (encoding visfatin, <xref ref-type="fig" rid="pone-0001765-g001">Figure 1C</xref>) or <italic>RETN</italic> (encoding resistin, <xref ref-type="fig" rid="pone-0001765-g001">Figure 1D</xref>). Human albumin as a control did not significantly alter the expression of all these genes (<xref ref-type="fig" rid="pone-0001765-g001">Figure 1A&#x02013;D</xref>). The <italic>IL6</italic> mRNA expression in these cells was below the detection limit.</p><fig id="pone-0001765-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001765.g001</object-id><label>Figure 1</label><caption><title>mRNA expression in human THP1 monocytes following fetuin-A treatment.</title><p>Expression of <italic>TNF</italic> (A), <italic>IL1B</italic> (B), <italic>PBEF1</italic> (C), and <italic>RETN</italic> (D) mRNA in human THP1 monocytes before (control) and after treatment with human albumin or human fetuin-A for 8 h. Cellular mRNA contents were corrected for 28S-rRNA (RAU&#x0200a;&#x0003d;&#x0200a;relative arbitrary units). Data are given as means&#x000b1;SEM (n&#x0200a;&#x0003d;&#x0200a;5). Data were analyzed by ANOVA, followed by Dunnett's test.</p></caption><graphic xlink:href="pone.0001765.g001"/></fig></sec><sec id="s3b"><title>Effect of fetuin-A on adipose tissue Adipoq mRNA expression and circulating adiponectin in mice</title><p>Within 8 h, intraperitoneal bolus administration of human fetuin-A (0.5 mg/g body weight) into male C57BL/6 mice resulted in insulin resistance (fetuin-A-treated: 22.46&#x000b1;1.27 vs control: 10.21&#x000b1;1.65, T(4)&#x0200a;&#x0003d;&#x0200a;9.06, p&#x0200a;&#x0003d;&#x0200a;0.004) as estimated by the HOMA-IR. Furthermore, fetuin-A induced adipose tissue mRNA expression of the inflammatory genes <italic>Il6</italic> and <italic>Tnf</italic> 174- and 27-fold (ANOVA, F(9,7)&#x0200a;&#x0003d;&#x0200a;7.12, p&#x0200a;&#x0003d;&#x0200a;0.02, and F(9,7)&#x0200a;&#x0003d;&#x0200a;12.38, p&#x0200a;&#x0003d;&#x0200a;0.005, respectively, <xref ref-type="fig" rid="pone-0001765-g002">Figure 2A,B</xref>). This was accompanied by a 58&#x00025; decrease in adipose tissue <italic>Adipoq</italic> mRNA content as compared to control (ANOVA, F(9,7)&#x0200a;&#x0003d;&#x0200a;6.15, p&#x0200a;&#x0003d;&#x0200a;0.038, <xref ref-type="fig" rid="pone-0001765-g002">Figure 2C</xref>), that showed a strong trend after correction for multiple comparison (p&#x0200a;&#x0003d;&#x0200a;0.06). To validate these findings on <italic>Adipoq</italic> mRNA expression, we repeated the experiment and additionally measured serum adiponectin. In the second experiment, treatment of mice with a commercially available bovine fetuin-A (0.75 mg/g body weight) provoked a significant 45&#x00025; decrease in perigonadal adipose tissue <italic>Adipoq</italic> mRNA content as compared to baseline (T(4)&#x0200a;&#x0003d;&#x0200a;4.30, p&#x0200a;&#x0003d;&#x0200a;0.006), whereas no effect was seen in diluent-treated control animals (p&#x0200a;&#x0003d;&#x0200a;0.48). Concomitantly, serum adiponectin levels significantly decreased in fetuin-A-treated (T(4)&#x0200a;&#x0003d;&#x0200a;2.58, p&#x0200a;&#x0003d;&#x0200a;0.031), but not in diluent-treated mice (p&#x0200a;&#x0003d;&#x0200a;0.41). To assess specificity for adiponectin, we additionally quantified adipose tissue mRNA expression of other adipokine genes such as <italic>Lep</italic> (encoding leptin) and <italic>Rbp4</italic> (encoding retinol-binding protein 4). Fetuin-A did not modulate <italic>Lep</italic> (<xref ref-type="fig" rid="pone-0001765-g002">Figure 2D</xref>) or <italic>Rbp4</italic> (data not shown) mRNA expression. Treatment of mice with human albumin (0.5 mg/g body weight) did not significantly alter the expression of all these genes (all p&#x0003e;0.2, <xref ref-type="fig" rid="pone-0001765-g002">Figure 2A&#x02013;D</xref>).</p><fig id="pone-0001765-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001765.g002</object-id><label>Figure 2</label><caption><title>Cytokine and adipokine mRNA expression in adipose tissue of mice.</title><p>Adipose tissue expression of <italic>Il6</italic> (A), <italic>Tnf</italic> (B), <italic>Adipoq</italic> (C), and <italic>Lep</italic> (D) mRNA in mice after bolus treatment with human fetuin-A (0.5 mg/g body weight), human albumin (0.5 mg/g body weight), or diluent (control) for 8 h. Cellular mRNA contents were corrected for 28S-rRNA (RAU&#x0200a;&#x0003d;&#x0200a;relative arbitrary units). Data are given as means&#x000b1;SEM. Data were analyzed by ANOVA, followed by Dunnett's test.</p></caption><graphic xlink:href="pone.0001765.g002"/></fig></sec><sec id="s3c"><title>Effect of fetuin-A on ADIPOQ and cytokine mRNA expression of human in vitro differentiated adipocytes</title><p>To test whether suppression of <italic>Adipoq</italic> mRNA expression by fetuin-A is a direct effect on adipocytes and is not restricted to rodents, we treated <italic>in vitro</italic> differentiated human adipocytes from four donors with bovine or human fetuin-A (300 &#x000b5;g/ml) for 24 h. These procedures resulted in 30- and 50-&#x00025; reductions of <italic>ADIPOQ</italic> mRNA expression, respectively (T(3)&#x0200a;&#x0003d;&#x0200a;&#x02212;3.87, p&#x0200a;&#x0003d;&#x0200a;0.001 and T(3)&#x0200a;&#x0003d;&#x0200a;&#x02212;3.54, p&#x0200a;&#x0003d;&#x0200a;0.016, respectively, <xref ref-type="fig" rid="pone-0001765-g003">Figure 3</xref>). In analogy to our results in human THP1 monocytes, fetuin-A induced inflammatory markers in adipocytes as well (<italic>TNF</italic>: p&#x0200a;&#x0003d;&#x0200a;0.007; <italic>IL6</italic>: p&#x0200a;&#x0003d;&#x0200a;0.035; <italic>CCL2</italic>: p&#x0200a;&#x0003d;&#x0200a;0.03; <italic>IL1B</italic>: p&#x0200a;&#x0003d;&#x0200a;0.068, data not shown). To further investigate whether paracrine or autocrine effects of fetuin-A exist, we determined the fetuin-A mRNA expression in human THP1 monocytes and human adipose tissue and for comparison in human liver. While fetuin-A was expressed in liver tissue from human donors, it was not expressed in THP1 monocytes or adipose tissue (<xref ref-type="supplementary-material" rid="pone.0001765.s001">Figure S1</xref>). Furthermore, fetuin-A expression was not detected in adipose tissue from obese and insulin resistant Pima Indians (personal communication Dr. Paska Permana) suggesting that these conditions do not induce fetuin-A expression in adipose tissue in humans. Thus, these data strongly support that the endocrine action of fetuin-A mediates the aforementioned effects.</p><fig id="pone-0001765-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001765.g003</object-id><label>Figure 3</label><caption><title>Adiponectin mRNA expression in cultured human adipocytes.</title><p><italic>ADIPOQ</italic> mRNA expression of human <italic>in vitro</italic> differentiated adipocytes after treatment with bovine (A) and human (B) fetuin-A for 24 h. Cellular mRNA contents were corrected for 28S-rRNA. Data from adipocyte cultures of four donors are presented. Data were analyzed by Student's t-test.</p></caption><graphic xlink:href="pone.0001765.g003"/></fig></sec><sec id="s3d"><title>Relationship of plasma fetuin-A with circulating markers of inflammation and plasma adiponectin</title><p>To investigate whether plasma fetuin-A is associated with circulating markers of inflammation and circulating adiponectin in humans <italic>in vivo</italic>, we analyzed cross-sectional data from 122 subjects including 80 subjects with normal glucose tolerance, 40 subjects with impaired glucose tolerance, and two patients with newly diagnosed and untreated type 2 diabetes. The subjects covered a wide range of age, body fat content, waist circumference, and circulating fetuin-A (<xref ref-type="table" rid="pone-0001765-t002">Table 2</xref>). Plasma fetuin-A was not associated with circulating IL-6 and TNF-&#x003b1; (both p &#x02265; 0.82). This finding was not unexpected since both cytokines act in a paracrine, rather than in a systemic fashion <xref ref-type="bibr" rid="pone.0001765-Kershaw1">&#x0005b;30&#x0005d;</xref>. However, a positive correlation between circulating fetuin-A and hsCRP, a systemic marker of subclinical inflammation, was detected (r&#x0200a;&#x0003d;&#x0200a;0.26, p&#x0200a;&#x0003d;&#x0200a;0.01, n&#x0200a;&#x0003d;&#x0200a;94 with hsCRP above the detection limit of the ELISA). Furthermore, circulating fetuin-A and adiponectin were negatively correlated with each other (r&#x0200a;&#x0003d;&#x0200a;&#x02212;0.28, p&#x0200a;&#x0003d;&#x0200a;0.02).</p><table-wrap id="pone-0001765-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001765.t002</object-id><label>Table 2</label><caption><title>Demographics and metabolic characteristics of the subjects</title></caption><graphic id="pone-0001765-t002-2" xlink:href="pone.0001765.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001765-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Variables</td><td align="left" rowspan="1" colspan="1">Mean&#x000b1;SE</td><td align="left" rowspan="1" colspan="1">Range</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (Males/Females)</td><td align="left" rowspan="1" colspan="1">50/72</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">44&#x000b1;1</td><td align="left" rowspan="1" colspan="1">19&#x02013;65</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="left" rowspan="1" colspan="1">171&#x000b1;1</td><td align="left" rowspan="1" colspan="1">149&#x02013;193</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="left" rowspan="1" colspan="1">85&#x000b1;2</td><td align="left" rowspan="1" colspan="1">52&#x02013;166</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="left" rowspan="1" colspan="1">97&#x000b1;1</td><td align="left" rowspan="1" colspan="1">56&#x02013;150</td></tr><tr><td align="left" rowspan="1" colspan="1">Body fat (&#x00025;)</td><td align="left" rowspan="1" colspan="1">32&#x000b1;1</td><td align="left" rowspan="1" colspan="1">10&#x02013;54</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulin sensitivity (&#x000b5;M kg<sup>&#x02212;1</sup> min<sup>&#x02212;1</sup> pM<sup>&#x02212;1</sup>)</td><td align="left" rowspan="1" colspan="1">0.064&#x000b1;0.004</td><td align="left" rowspan="1" colspan="1">0.010&#x02013;0.200</td></tr><tr><td align="left" rowspan="1" colspan="1">hsCRP (mg/ml)</td><td align="left" rowspan="1" colspan="1">0.20&#x000b1;0.03</td><td align="left" rowspan="1" colspan="1">0.01&#x02013;1.54</td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1; (pg/ml)</td><td align="left" rowspan="1" colspan="1">4.19&#x000b1;0.81</td><td align="left" rowspan="1" colspan="1">0.06&#x02013;55.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Il-6 (pg/ml)</td><td align="left" rowspan="1" colspan="1">0.93&#x000b1;0.23</td><td align="left" rowspan="1" colspan="1">0.04&#x02013;25.93</td></tr><tr><td align="left" rowspan="1" colspan="1">Total adiponectin (&#x000b5;g/ml)</td><td align="left" rowspan="1" colspan="1">9.00&#x000b1;0.41</td><td align="left" rowspan="1" colspan="1">2.92&#x02013;24.58</td></tr><tr><td align="left" rowspan="1" colspan="1">Total adiponectin (&#x000b5;g/ml)<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">6.43&#x000b1;0.44</td><td align="left" rowspan="1" colspan="1">2.45&#x02013;17.47</td></tr><tr><td align="left" rowspan="1" colspan="1">LMW adiponectin (&#x000b5;g/ml)<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">2.36&#x000b1;0.24</td><td align="left" rowspan="1" colspan="1">0.46&#x02013;8.83</td></tr><tr><td align="left" rowspan="1" colspan="1">MMW adiponectin (&#x000b5;g/ml)<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">1.49&#x000b1;0.15</td><td align="left" rowspan="1" colspan="1">0.30&#x02013;4.86</td></tr><tr><td align="left" rowspan="1" colspan="1">HMW adiponectin (&#x000b5;g/ml)<xref ref-type="table-fn" rid="nt103">&#x0002a;</xref></td><td align="left" rowspan="1" colspan="1">2.58&#x000b1;0.24</td><td align="left" rowspan="1" colspan="1">0.49&#x02013;7.81</td></tr><tr><td align="left" rowspan="1" colspan="1">Fetuin-A (&#x000b5;g/ml)</td><td align="left" rowspan="1" colspan="1">264&#x000b1;10</td><td align="left" rowspan="1" colspan="1">111&#x02013;604</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><p>Values are mean (SE);</p></fn><fn id="nt103"><label>&#x0002a;</label><p>available in 49 subjects</p></fn></table-wrap-foot></table-wrap><p>Next, we assessed the role of plasma fetuin-A as a determinant of circulating adiponectin and its independence of other known determinants of circulating adiponectin by multivariate linear regression analysis (<xref ref-type="table" rid="pone-0001765-t003">Table 3</xref>). Circulating adiponectin was chosen as the dependent variable, and gender, age, body fat, and waist circumference were used as covariates and added step by step (<xref ref-type="table" rid="pone-0001765-t003">Table 3</xref>, models 1&#x02013;4). This procedure gradually increased the r<sup>2</sup> of the model to 0.39 (<xref ref-type="table" rid="pone-0001765-t003">Table 3</xref>, model 4). Inclusion of plasma fetuin-A as an additional covariate further increased the r<sup>2</sup> to 0.42, and plasma fetuin-A concentration turned out to be an independent determinant of circulating adiponectin (<xref ref-type="table" rid="pone-0001765-t003">Table 3</xref>, model 5).</p><table-wrap id="pone-0001765-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001765.t003</object-id><label>Table 3</label><caption><title>Determinants of circulating adiponectin in humans in multivariate linear regression models</title></caption><graphic id="pone-0001765-t003-3" xlink:href="pone.0001765.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0001765-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Covariates</td><td align="left" rowspan="1" colspan="1">Estimate&#x000b1;SE</td><td align="left" rowspan="1" colspan="1">p</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Model 1 (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.31)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">0.268&#x000b1;0.036</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Model 2 (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.34)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">0.275&#x000b1;0.036</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">0.261&#x000b1;0.036</td><td align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Model 3 (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.38)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">0.335&#x000b1;0.041</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">0.239&#x000b1;0.116</td><td align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" rowspan="1" colspan="1">Body fat</td><td align="left" rowspan="1" colspan="1">&#x02212;1.224&#x000b1;0.441</td><td align="left" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Model 4 (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.39)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">0.253&#x000b1;0.062</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">0.268&#x000b1;0.117</td><td align="left" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Body fat</td><td align="left" rowspan="1" colspan="1">&#x02212;0.376&#x000b1;0.650</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference</td><td align="left" rowspan="1" colspan="1">&#x02212;0.634&#x000b1;0.359</td><td align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Model 5 (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.42)</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Female sex</td><td align="left" rowspan="1" colspan="1">0.247&#x000b1;0.061</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">0.187&#x000b1;0.119</td><td align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td align="left" rowspan="1" colspan="1">Body fat</td><td align="left" rowspan="1" colspan="1">&#x02212;0.293&#x000b1;0.638</td><td align="left" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference</td><td align="left" rowspan="1" colspan="1">&#x02212;0.601&#x000b1;0.352</td><td align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma Fetuin-A</td><td align="left" rowspan="1" colspan="1">&#x02212;0.234&#x000b1;0.097</td><td align="left" rowspan="1" colspan="1">0.02</td></tr></tbody></table></table-wrap></sec><sec id="s3e"><title>Relationship between fetuin-A and multimeric forms of adiponectin</title><p>Plasma adiponectin circulates in several multimeric forms, i.e. trimeric low molecular weight (LMW), hexameric middle molecular weight (MMW) as well as more complex high molecular weight (HMW) structures <xref ref-type="bibr" rid="pone.0001765-Tsao1">&#x0005b;31&#x0005d;</xref>. We assessed whether fetuin-A affects the formation of a certain form in a subgroup of 49 subjects who underwent the clamp and had plasma samples stored at &#x02212;80&#x000b0;C (21 men, 28 women; 23&#x02013;64 years; 16.0&#x02013;50.0&#x00025; body fat; 68&#x02013;119 cm waist circumference). In this subgroup, total plasma adiponectin was positively correlated with hyperinsulinemic euglycemic clamp-derived insulin sensitivity adjusted for gender, age, and body fat (r&#x0200a;&#x0003d;&#x0200a;0.40, p&#x0200a;&#x0003d;&#x0200a;0.005). Furthermore, plasma fetuin-A tended to negatively correlate with the adjusted insulin sensitivity (r&#x0200a;&#x0003d;&#x0200a;&#x02212;0.25, p&#x0200a;&#x0003d;&#x0200a;0.08) reflecting our recent data <xref ref-type="bibr" rid="pone.0001765-Stefan2">&#x0005b;24&#x0005d;</xref>. Plasma fetuin-A correlated negatively with total adiponectin (<xref ref-type="fig" rid="pone-0001765-g004">Figure 4A</xref>) and, in particular, with HMW (<xref ref-type="fig" rid="pone-0001765-g004">Figure 4B</xref>) and MMW (<xref ref-type="fig" rid="pone-0001765-g004">Figure 4C</xref>) adiponectin, but not with LMW adiponectin (<xref ref-type="fig" rid="pone-0001765-g004">Figure 4D</xref>).</p><fig id="pone-0001765-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0001765.g004</object-id><label>Figure 4</label><caption><title>Relationships between circulating fetuin-A and circulating adiponectin in humans.</title><p>Relationship between plasma levels of fetuin-A with total adiponectin and adiponectin's multimeric forms (A&#x02013;D) in 49 healthy human subjects after adjustment of log-transformed data for age, sex, and percentage of body fat by multivariate linear regression analysis. The regression coefficients as well as the p-value are indicated (HMW&#x02013;high molecular weight; LMW&#x02013;low molecular weight; MMW&#x02013;middle molecular weight).</p></caption><graphic xlink:href="pone.0001765.g004"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>Fetuin-A is a major plasma glycoprotein which was discovered in 1944 <xref ref-type="bibr" rid="pone.0001765-Pedersen1">&#x0005b;32&#x0005d;</xref>. For a long time, its biological function remained obscure. Using targeted gene disruption, fetuin-A was recently reported to inhibit ectopic calcification <xref ref-type="bibr" rid="pone.0001765-JahnenDechent1">&#x0005b;33&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001765-Schafer1">&#x0005b;34&#x0005d;</xref>. In keeping with this, fetuin-A deficiency in humans was found to be associated with vascular calcification and mortality in patients on hemodialysis <xref ref-type="bibr" rid="pone.0001765-Ketteler1">&#x0005b;35&#x0005d;</xref>. However, fetuin-A might exert more functions: several studies demonstrated that fetuin-A can act as a natural inhibitor of the insulin receptor tyrosine kinase in liver and skeletal muscle <xref ref-type="bibr" rid="pone.0001765-Auberger1">&#x0005b;3&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001765-Mathews2">&#x0005b;7&#x0005d;</xref>, and fetuin-A knockout mice display improved insulin sensitivity and are resistant to weight gain upon a high-fat diet <xref ref-type="bibr" rid="pone.0001765-Mathews3">&#x0005b;8&#x0005d;</xref>.</p><p>Besides the effects of fetuin-A on muscle and liver insulin signalling, there is increasing evidence that fetuin-A is important for insulin action in adipose tissue <xref ref-type="bibr" rid="pone.0001765-Dahlman1">&#x0005b;10&#x0005d;</xref>. Moreover, the variability of plasma adiponectin levels is largely explained by a locus on human chromosome 3q27 harbouring both <italic>ADIPOQ</italic> and, in direct vicinity, <italic>AHSG</italic>. It is of note that not all variability in plasma adiponectin is explained by genetic variation of the <italic>ADIPOQ</italic> gene <xref ref-type="bibr" rid="pone.0001765-Pollin1">&#x0005b;23&#x0005d;</xref>. This led us to investigate whether fetuin-A regulates adiponectin production and, thus, may explain the recently reported association between fetuin-A and the metabolic syndrome <xref ref-type="bibr" rid="pone.0001765-Stefan2">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001765-Mori1">&#x0005b;25&#x0005d;</xref>. In addition, the metabolic syndrome and hypoadiponectinemia are strongly associated with low-grade inflammation <xref ref-type="bibr" rid="pone.0001765-Trujillo1">&#x0005b;27&#x0005d;</xref>. Furthermore, high circulating fetuin-A was found to be associated with carotid arterial stiffness <xref ref-type="bibr" rid="pone.0001765-Mori2">&#x0005b;36&#x0005d;</xref>, a functional property of atherosclerosis that is accompanied by subclinical inflammation. Therefore, we further tested whether fetuin-A treatment affects expression of inflammatory cytokines, a critical step in the generation of low-grade inflammation.</p><p>With the present report, we provide novel data that highly purified fetuin-A exerts strong pro-inflammatory effects as it provoked cytokine expression in monocytes <italic>in vitro</italic>. The latter are known to infiltrate hypertrophic adipose tissue and to essentially contribute to adipose tissue inflammation <xref ref-type="bibr" rid="pone.0001765-Weisberg1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0001765-Xu1">&#x0005b;38&#x0005d;</xref>. In addition, we found that, in animals <italic>in vivo,</italic> fetuin-A treatment increased adipose tissue RNA expression of <italic>Il6</italic> and <italic>Tnf</italic> 174- and 27-fold, respectively.</p><p>Besides the effects of fetuin-A on the expression of these inflammatory cytokines, administration of fetuin-A into mice repressed <italic>Adipoq</italic> mRNA expression in adipose tissue and decreased circulating adiponectin. <italic>Lep</italic> and <italic>Rbp4</italic> mRNA expression were not affected by fetuin-A, and albumin did not impair <italic>Adipoq</italic> mRNA expression. These findings provide evidence that the effect of fetuin-A on <italic>Adipoq</italic> expression is not due to a general trophic effect <xref ref-type="bibr" rid="pone.0001765-Lyles1">&#x0005b;39&#x0005d;</xref>. Furthermore, fetuin-A directly affected adipocyte gene expression and these findings were not restricted to rodents: it repressed <italic>ADIPOQ</italic> expression of <italic>in vitro</italic> differentiated human adipocytes.</p><p>Based on these findings <italic>in vitro</italic> and in animals, we further investigated whether circulating fetuin-A was related to low-grade inflammation and circulating adiponectin in humans. Indeed, plasma fetuin-A levels correlated positively with hsCRP levels, as reported previously by Ix <italic>et al</italic>. <xref ref-type="bibr" rid="pone.0001765-Ix1">&#x0005b;26&#x0005d;</xref>.</p><p>These findings are somewhat unexpected because CRP is up-regulated in inflammatory states while acute inflammation down-regulates fetuin-A expression in the liver <xref ref-type="bibr" rid="pone.0001765-Ruminy1">&#x0005b;40&#x0005d;</xref>. Whether, the latter effect is transient and/or reflects compensational mechanisms, needs to be determined. Furthermore, plasma fetuin-A levels correlated negatively with plasma adiponectin levels. In addition, besides other determinants of adiponectin levels, plasma fetuin-A levels were identified as a contributor to the variability in circulating adiponectin. Of note, the observed relationships of fetuin-A with adiponectin in humans were not very strong, nevertheless, they remained statistically significant after adjustment for established determinants of plasma adiponectin levels. This finding supports the assumption of Ix <italic>et al.</italic><xref ref-type="bibr" rid="pone.0001765-Ix1">&#x0005b;26&#x0005d;</xref> that the strong relationship between plasma fetuin-A levels and the metabolic syndrome may be a result of fetuin-A-induced suppression of adiponectin production.</p><p>In addition, fetuin-A was specifically associated with HMW and MMW forms of adiponectin, but not with the LMW form. HMW adiponectin is reported to be the most active adiponectin form <xref ref-type="bibr" rid="pone.0001765-Hara1">&#x0005b;41&#x0005d;</xref> and represents, among all multimeric forms of adiponectin, the major determinant of insulin resistance, an atherogenic lipoprotein profile, and the metabolic syndrome <xref ref-type="bibr" rid="pone.0001765-Hara1">&#x0005b;41&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001765-LaraCastro1">&#x0005b;43&#x0005d;</xref>. How fetuin-A determines the assembly of trimeric adiponectin into hexameric MMW and higher-order HMW structures, a process that is supposed to occur during the entry of adiponectin into the bloodstream <xref ref-type="bibr" rid="pone.0001765-Tsao1">&#x0005b;31&#x0005d;</xref>, is currently unknown and needs further investigation.</p><p>So far, no information is available on fetuin-A-specific cell surface receptors and intracellular signaling pathways making it difficult to assess the molecular mechanisms underlying fetuin-A-induced repression of <italic>ADIPOQ</italic> expression in adipocytes as well as fetuin-A-mediated induction of cytokine expression in monocytes and adipocytes. Since the <italic>ADIPOQ</italic> gene is under the control of the transcription factor peroxisome proliferator-activated receptor (PPAR) &#x003b3;, we also assessed whether PPAR&#x003b3; expression was altered by fetuin-A treatment. Whereas fetuin-A reduced adipose tissue PPAR&#x003b3; expression in mice in vivo, PPAR&#x003b3; expression of adipocytes was not affected (data not shown). The down-regulation of adiponectin and possibly PPAR&#x003b3; expression, appears contradicting to the reported pro-adipogenic effect of fetuin-A <xref ref-type="bibr" rid="pone.0001765-Schmidt1">&#x0005b;11&#x0005d;</xref>. However, this observation may be due to differential effects of fetuin-A on mature adipocytes and pre-adipocytes, respectively.</p><p>Since we observed a strong effect of fetuin-A on cytokine expression, and IL-6 and TNF-&#x003b1; are well-described negative regulators of adiponectin expression and production <xref ref-type="bibr" rid="pone.0001765-Fasshauer1">&#x0005b;44&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001765-Sopasakis1">&#x0005b;49&#x0005d;</xref>, we suppose that fetuin-A-induced impairment of adiponectin synthesis may be at least partially mediated by effects of fetuin-A on IL-6 and TNF-&#x003b1; production. Whether this is an exclusive mechanism, or whether fetuin-A regulates adiponectin expression and secretion independently of cytokine production, needs to be determined in future studies.</p><p>Together, the results presented in this work advance our understanding of the role of fetuin-A in the pathophysiology of insulin resistance, atherosclerosis, and the metabolic syndrome. Hepatic steatosis that is strongly related to insulin resistance and type 2 diabetes <xref ref-type="bibr" rid="pone.0001765-Roden1">&#x0005b;50&#x0005d;</xref>, associates with enhanced hepatic fetuin-A production in rats <xref ref-type="bibr" rid="pone.0001765-Lin1">&#x0005b;51&#x0005d;</xref> and humans <xref ref-type="bibr" rid="pone.0001765-Stefan2">&#x0005b;24&#x0005d;</xref>. Elevated circulating levels of fetuin-A negatively affect whole-body insulin sensitivity (i) by impairment of insulin signaling in muscle and liver <xref ref-type="bibr" rid="pone.0001765-Auberger1">&#x0005b;3&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0001765-Mathews2">&#x0005b;7&#x0005d;</xref> and (ii) by triggering inflammation in adipose tissue and suppression of adiponectin production. Generation of an atherogenic lipoprotein profile <xref ref-type="bibr" rid="pone.0001765-Chan1">&#x0005b;52&#x0005d;</xref>, induction of inflammatory cytokines as well as suppression of the atheroprotective hormone adiponectin <xref ref-type="bibr" rid="pone.0001765-Lam1">&#x0005b;53&#x0005d;</xref>, therefore, represent plausible molecular pathways linking fatty liver and atherosclerosis <xref ref-type="bibr" rid="pone.0001765-Santoliquido1">&#x0005b;54&#x0005d;</xref>. In addition, based on the findings from fetuin-A deficient mice that remain lean and insulin sensitive fed a high-fat diet <xref ref-type="bibr" rid="pone.0001765-Mathews3">&#x0005b;8&#x0005d;</xref>, fetuin-A may have long-term effects on energy expenditure and lipid oxidation, independent of the aforementioned mechanisms.</p><p>In conclusion, we found that fetuin-A induces low-grade inflammation and represses adiponectin production in animals and in humans. These data provide novel evidence on the role of fatty liver in the pathophysiology of insulin resistance and atherosclerosis.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0001765.s001"><label>Figure S1</label><caption><p>(0.50 MB TIF)</p></caption><media xlink:href="pone.0001765.s001.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank all study participants for their cooperation. We gratefully acknowledge the excellent technical assistance of Anna Bury and Heike Luz who were involved in the clinical tests and Melanie Weisser and Alke Guirguis who were involved in the analytical procedures.</p></ack><ref-list><title>References</title><ref id="pone.0001765-Dziegielewska1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dziegielewska</surname><given-names>KM</given-names></name><name><surname>Brown</surname><given-names>WM</given-names></name><name><surname>Casey</surname><given-names>SJ</given-names></name><name><surname>Christie</surname><given-names>DL</given-names></name><name><surname>Foreman</surname><given-names>RC</given-names></name><etal/></person-group><year>1990</year><article-title>The complete cDNA and amino acid sequence of bovine fetuin. Its homology with alpha 2HS glycoprotein and relation to other members of the cystatin superfamily.</article-title><source>J Biol Chem</source><volume>265</volume><fpage>4354</fpage><lpage>4357</lpage><pub-id pub-id-type="pmid">1689725</pub-id></citation></ref><ref id="pone.0001765-Denecke1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Denecke</surname><given-names>B</given-names></name><name><surname>Graber</surname><given-names>S</given-names></name><name><surname>Schafer</surname><given-names>C</given-names></name><name><surname>Heiss</surname><given-names>A</given-names></name><name><surname>Woltje</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A.</article-title><source>Biochem J</source><volume>376</volume><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">12943536</pub-id></citation></ref><ref id="pone.0001765-Auberger1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Auberger</surname><given-names>P</given-names></name><name><surname>Falquerho</surname><given-names>L</given-names></name><name><surname>Contreres</surname><given-names>JO</given-names></name><name><surname>Pages</surname><given-names>G</given-names></name><name><surname>Le Cam</surname><given-names>G</given-names></name><etal/></person-group><year>1989</year><article-title>Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity.</article-title><source>Cell</source><volume>58</volume><fpage>631</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">2766355</pub-id></citation></ref><ref id="pone.0001765-Rauth1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rauth</surname><given-names>G</given-names></name><name><surname>Poschke</surname><given-names>O</given-names></name><name><surname>Fink</surname><given-names>E</given-names></name><name><surname>Eulitz</surname><given-names>M</given-names></name><name><surname>Tippmer</surname><given-names>S</given-names></name><etal/></person-group><year>1992</year><article-title>The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor.</article-title><source>Eur J Biochem</source><volume>204</volume><fpage>523</fpage><lpage>529</lpage><pub-id pub-id-type="pmid">1371750</pub-id></citation></ref><ref id="pone.0001765-Srinivas1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Srinivas</surname><given-names>PR</given-names></name><name><surname>Wagner</surname><given-names>AS</given-names></name><name><surname>Reddy</surname><given-names>LV</given-names></name><name><surname>Deutsch</surname><given-names>DD</given-names></name><name><surname>Leon</surname><given-names>MA</given-names></name><etal/></person-group><year>1993</year><article-title>Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level.</article-title><source>Mol Endocrinol</source><volume>7</volume><fpage>1445</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">7906861</pub-id></citation></ref><ref id="pone.0001765-Mathews1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathews</surname><given-names>ST</given-names></name><name><surname>Srinivas</surname><given-names>PR</given-names></name><name><surname>Leon</surname><given-names>MA</given-names></name><name><surname>Grunberger</surname><given-names>G</given-names></name></person-group><year>1997</year><article-title>Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase.</article-title><source>Life Sci</source><volume>61</volume><fpage>1583</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">9353167</pub-id></citation></ref><ref id="pone.0001765-Mathews2"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathews</surname><given-names>ST</given-names></name><name><surname>Chellam</surname><given-names>N</given-names></name><name><surname>Srinivas</surname><given-names>PR</given-names></name><name><surname>Cintron</surname><given-names>VJ</given-names></name><name><surname>Leon</surname><given-names>MA</given-names></name><etal/></person-group><year>2000</year><article-title>Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor.</article-title><source>Mol Cell Endocrinol</source><volume>164</volume><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">11026561</pub-id></citation></ref><ref id="pone.0001765-Mathews3"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mathews</surname><given-names>ST</given-names></name><name><surname>Singh</surname><given-names>GP</given-names></name><name><surname>Ranalletta</surname><given-names>M</given-names></name><name><surname>Cintron</surname><given-names>VJ</given-names></name><name><surname>Qiang</surname><given-names>X</given-names></name><etal/></person-group><year>2002</year><article-title>Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene.</article-title><source>Diabetes</source><volume>51</volume><fpage>2450</fpage><lpage>2458</lpage><pub-id pub-id-type="pmid">12145157</pub-id></citation></ref><ref id="pone.0001765-Siddiq1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siddiq</surname><given-names>A</given-names></name><name><surname>Lepretre</surname><given-names>F</given-names></name><name><surname>Hercberg</surname><given-names>S</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Gibson</surname><given-names>F</given-names></name></person-group><year>2005</year><article-title>A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians.</article-title><source>Diabetes</source><volume>54</volume><fpage>2477</fpage><lpage>2481</lpage><pub-id pub-id-type="pmid">16046317</pub-id></citation></ref><ref id="pone.0001765-Dahlman1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahlman</surname><given-names>I</given-names></name><name><surname>Eriksson</surname><given-names>P</given-names></name><name><surname>Kaaman</surname><given-names>M</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><etal/></person-group><year>2004</year><article-title>alpha2-Heremans-Schmid glycoprotein gene polymorphisms are associated with adipocyte insulin action.</article-title><source>Diabetologia</source><volume>47</volume><fpage>1974</fpage><lpage>1979</lpage><pub-id pub-id-type="pmid">15599699</pub-id></citation></ref><ref id="pone.0001765-Schmidt1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>W</given-names></name><name><surname>P&#x000f6;ll-Jordan</surname><given-names>G</given-names></name><name><surname>L&#x000f6;ffler</surname><given-names>G</given-names></name></person-group><year>1990</year><article-title>Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP.</article-title><source>J Biol Chem.</source><volume>15;265</volume><fpage>15489</fpage><lpage>15495</lpage><pub-id pub-id-type="pmid">1697591</pub-id></citation></ref><ref id="pone.0001765-Kadowaki1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kubota</surname><given-names>N</given-names></name><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Ueki</surname><given-names>K</given-names></name><etal/></person-group><year>2006</year><article-title>Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.</article-title><source>J Clin Invest</source><volume>116</volume><fpage>1784</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">16823476</pub-id></citation></ref><ref id="pone.0001765-Weyer1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weyer</surname><given-names>C</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Hotta</surname><given-names>K</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><etal/></person-group><year>2001</year><article-title>Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.</article-title><source>J Clin Endocrinol Metab</source><volume>86</volume><fpage>1930</fpage><lpage>1935</lpage><pub-id pub-id-type="pmid">11344187</pub-id></citation></ref><ref id="pone.0001765-Stefan1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Vozarova</surname><given-names>B</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><name><surname>Matsuzawa</surname><given-names>Y</given-names></name><name><surname>Weyer</surname><given-names>C</given-names></name><etal/></person-group><year>2002</year><article-title>Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans.</article-title><source>Diabetes</source><volume>51</volume><fpage>1884</fpage><lpage>1888</lpage><pub-id pub-id-type="pmid">12031977</pub-id></citation></ref><ref id="pone.0001765-Tschritter1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tschritter</surname><given-names>O</given-names></name><name><surname>Fritsche</surname><given-names>A</given-names></name><name><surname>Thamer</surname><given-names>C</given-names></name><name><surname>Haap</surname><given-names>M</given-names></name><name><surname>Shirkavand</surname><given-names>F</given-names></name><etal/></person-group><year>2003</year><article-title>Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism.</article-title><source>Diabetes</source><volume>52</volume><fpage>239</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">12540592</pub-id></citation></ref><ref id="pone.0001765-Bacha1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bacha</surname><given-names>F</given-names></name><name><surname>Saad</surname><given-names>R</given-names></name><name><surname>Gungor</surname><given-names>N</given-names></name><name><surname>Arslanian</surname><given-names>SA</given-names></name></person-group><year>2000</year><article-title>Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function.</article-title><source>Diabetes Care</source><volume>27</volume><fpage>547</fpage><lpage>552</lpage><pub-id pub-id-type="pmid">14747242</pub-id></citation></ref><ref id="pone.0001765-Pischon1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pischon</surname><given-names>T</given-names></name><name><surname>Girman</surname><given-names>CJ</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><etal/></person-group><year>2004</year><article-title>Plasma adiponectin levels and risk of myocardial infarction in men.</article-title><source>JAMA</source><volume>291</volume><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="pmid">15082700</pub-id></citation></ref><ref id="pone.0001765-Iglseder1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Iglseder</surname><given-names>B</given-names></name><name><surname>Mackevics</surname><given-names>V</given-names></name><name><surname>Stadlmayer</surname><given-names>A</given-names></name><name><surname>Tasch</surname><given-names>G</given-names></name><name><surname>Ladurner</surname><given-names>G</given-names></name><etal/></person-group><year>2005</year><article-title>Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study.</article-title><source>Stroke</source><volume>36</volume><fpage>2577</fpage><lpage>2582</lpage><pub-id pub-id-type="pmid">16282542</pub-id></citation></ref><ref id="pone.0001765-Schulze1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>MB</given-names></name><name><surname>Shai</surname><given-names>I</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Rifai</surname><given-names>M</given-names></name><etal/></person-group><year>2005</year><article-title>Adiponectin and future coronary heart disease events among men with type 2 diabetes.</article-title><source>Diabetes</source><volume>54</volume><fpage>534</fpage><lpage>539</lpage><pub-id pub-id-type="pmid">15677512</pub-id></citation></ref><ref id="pone.0001765-Rothenbacher1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothenbacher</surname><given-names>D</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name><name><surname>Marz</surname><given-names>W</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name></person-group><year>2005</year><article-title>Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers.</article-title><source>Eur Heart J</source><volume>26</volume><fpage>1640</fpage><lpage>1646</lpage><pub-id pub-id-type="pmid">15932907</pub-id></citation></ref><ref id="pone.0001765-Vionnet1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vionnet</surname><given-names>N</given-names></name><name><surname>Hani</surname><given-names>El-H</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Gallina</surname><given-names>S</given-names></name><name><surname>Francke</surname><given-names>S</given-names></name><etal/></person-group><year>200</year><article-title>Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24.</article-title><source>Am J Hum Genet</source><volume>67</volume><fpage>1470</fpage><lpage>1480</lpage><pub-id pub-id-type="pmid">11067779</pub-id></citation></ref><ref id="pone.0001765-Kissebah1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kissebah</surname><given-names>AH</given-names></name><name><surname>Sonnenberg</surname><given-names>GE</given-names></name><name><surname>Myklebust</surname><given-names>J</given-names></name><name><surname>Goldstein</surname><given-names>M</given-names></name><name><surname>Broman</surname><given-names>K</given-names></name><etal/></person-group><year>2000</year><article-title>Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome.</article-title><source>Proc Natl Acad Sci U S A</source><volume>97</volume><fpage>14478</fpage><lpage>14483</lpage><pub-id pub-id-type="pmid">11121050</pub-id></citation></ref><ref id="pone.0001765-Pollin1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pollin</surname><given-names>TI</given-names></name><name><surname>Tanner</surname><given-names>K</given-names></name><name><surname>O'connell</surname><given-names>JR</given-names></name><name><surname>Ott</surname><given-names>SH</given-names></name><name><surname>Damcott</surname><given-names>CM</given-names></name><etal/></person-group><year>2005</year><article-title>Linkage of plasma adiponectin levels to 3q27 explained by association with variation in the APM1 gene.</article-title><source>Diabetes</source><volume>54</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">15616038</pub-id></citation></ref><ref id="pone.0001765-Stefan2"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stefan</surname><given-names>N</given-names></name><name><surname>Hennige</surname><given-names>AM</given-names></name><name><surname>Staiger</surname><given-names>H</given-names></name><name><surname>Machann</surname><given-names>J</given-names></name><name><surname>Schick</surname><given-names>F</given-names></name><etal/></person-group><year>2006</year><article-title>Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans.</article-title><source>Diabetes Care</source><volume>29</volume><fpage>853</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">16567827</pub-id></citation></ref><ref id="pone.0001765-Mori1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Emoto</surname><given-names>M</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Araki</surname><given-names>T</given-names></name><name><surname>Teramura</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects.</article-title><source>Diabetes Care</source><volume>29</volume><fpage>468</fpage><pub-id pub-id-type="pmid">16443916</pub-id></citation></ref><ref id="pone.0001765-Ix1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ix</surname><given-names>JH</given-names></name><name><surname>Shlipak</surname><given-names>MG</given-names></name><name><surname>Brandenburg</surname><given-names>VM</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Ketteler</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study.</article-title><source>Circulation</source><volume>113</volume><fpage>1760</fpage><lpage>1767</lpage><pub-id pub-id-type="pmid">16567568</pub-id></citation></ref><ref id="pone.0001765-Trujillo1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trujillo</surname><given-names>ME</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name></person-group><year>2006</year><article-title>Adipose tissue-derived factors: impact on health and disease.</article-title><source>Endocr Rev. 2006</source><volume>27</volume><fpage>762</fpage><lpage>78</lpage></citation></ref><ref id="pone.0001765-Schling1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schling</surname><given-names>P</given-names></name><name><surname>Mallow</surname><given-names>H</given-names></name><name><surname>Trindl</surname><given-names>A</given-names></name><name><surname>Loffler</surname><given-names>G</given-names></name></person-group><year>1999</year><article-title>Evidence for a local renin angiotensin system in primary cultured human preadipocytes.</article-title><source>Int J Obes Relat Metab Disord</source><volume>23</volume><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">10340809</pub-id></citation></ref><ref id="pone.0001765-Matthews1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Hosker</surname><given-names>JP</given-names></name><name><surname>Rudenski</surname><given-names>AS</given-names></name><name><surname>Naylor</surname><given-names>BA</given-names></name><name><surname>Treacher</surname><given-names>DF</given-names></name><name><surname>Turner</surname><given-names>RC</given-names></name></person-group><year>1985</year><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.</article-title><source>Diabetologia</source><volume>28</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">3899825</pub-id></citation></ref><ref id="pone.0001765-Kershaw1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kershaw</surname><given-names>EE</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name></person-group><year>2004</year><article-title>Adipose tissue as an endocrine organ.</article-title><source>J Clin Endocrinol Metab</source><volume>89</volume><fpage>2548</fpage><lpage>2556</lpage><pub-id pub-id-type="pmid">15181022</pub-id></citation></ref><ref id="pone.0001765-Tsao1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>TS</given-names></name><name><surname>Murrey</surname><given-names>HE</given-names></name><name><surname>Hug</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name></person-group><year>2002</year><article-title>Oligomerization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30).</article-title><source>J Biol Chem</source><volume>277</volume><fpage>29359</fpage><lpage>29362</lpage><pub-id pub-id-type="pmid">12087086</pub-id></citation></ref><ref id="pone.0001765-Pedersen1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>KO</given-names></name></person-group><year>1944</year><article-title>Fetuin, a new globulin isolated from serum.</article-title><source>Nature</source><volume>154</volume><fpage>575</fpage></citation></ref><ref id="pone.0001765-JahnenDechent1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jahnen-Dechent</surname><given-names>W</given-names></name><name><surname>Schafer</surname><given-names>C</given-names></name><name><surname>Heiss</surname><given-names>A</given-names></name><name><surname>Grotzinger</surname><given-names>J</given-names></name></person-group><year>2001</year><article-title>Systemic inhibition of spontaneous calcification by the serum protein alpha 2-HS glycoprotein/fetuin.</article-title><source>Z Kardiol</source><volume>90</volume><issue>Suppl 3</issue><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">11374033</pub-id></citation></ref><ref id="pone.0001765-Schafer1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>C</given-names></name><name><surname>Heiss</surname><given-names>A</given-names></name><name><surname>Schwarz</surname><given-names>A</given-names></name><name><surname>Westenfeld</surname><given-names>R</given-names></name><name><surname>Ketteler</surname><given-names>M</given-names></name></person-group><year>2003</year><article-title>The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification.</article-title><source>J Clin Invest</source><volume>112</volume><fpage>357</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">12897203</pub-id></citation></ref><ref id="pone.0001765-Ketteler1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ketteler</surname><given-names>M</given-names></name><name><surname>Bongartz</surname><given-names>P</given-names></name><name><surname>Westenfeld</surname><given-names>R</given-names></name><name><surname>Wildberger</surname><given-names>JE</given-names></name><name><surname>Mahnken</surname><given-names>AH</given-names></name><etal/></person-group><year>2003</year><article-title>Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study.</article-title><source>Lancet</source><volume>361</volume><fpage>827</fpage><lpage>833</lpage><pub-id pub-id-type="pmid">12642050</pub-id></citation></ref><ref id="pone.0001765-Mori2"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Emoto</surname><given-names>M</given-names></name><name><surname>Araki</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Teramura</surname><given-names>M</given-names></name><etal/></person-group><year>2007</year><article-title>Association of serum fetuin-A with carotid arterial stiffness.</article-title><source>Clin Endocrinol (Oxf)</source><volume>66</volume><fpage>246</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17223995</pub-id></citation></ref><ref id="pone.0001765-Weisberg1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weisberg</surname><given-names>SP</given-names></name><name><surname>McCann</surname><given-names>D</given-names></name><name><surname>Desai</surname><given-names>M</given-names></name><name><surname>Rosenbaum</surname><given-names>M</given-names></name><name><surname>Leibel</surname><given-names>RL</given-names></name><etal/></person-group><year>2003</year><article-title>Obesity is associated with macrophage accumulation in adipose tissue.</article-title><source>J Clin Invest</source><volume>112</volume><fpage>1796</fpage><lpage>1808</lpage><pub-id pub-id-type="pmid">14679176</pub-id></citation></ref><ref id="pone.0001765-Xu1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Barnes</surname><given-names>GT</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><etal/></person-group><year>2003</year><article-title>Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance.</article-title><source>J Clin Invest</source><volume>112</volume><fpage>1821</fpage><lpage>1830</lpage><pub-id pub-id-type="pmid">14679177</pub-id></citation></ref><ref id="pone.0001765-Lyles1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyles</surname><given-names>JM</given-names></name><name><surname>Amin</surname><given-names>W</given-names></name><name><surname>Bock</surname><given-names>E</given-names></name><name><surname>Weill</surname><given-names>CL</given-names></name></person-group><year>1993</year><article-title>Regulation of NCAM by growth factors in serum-free myotube cultures.</article-title><source>J Neurosci Res</source><volume>34</volume><fpage>273</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">8384266</pub-id></citation></ref><ref id="pone.0001765-Ruminy1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruminy</surname><given-names>P</given-names></name><name><surname>Gangneux</surname><given-names>C</given-names></name><name><surname>Claeyssens</surname><given-names>S</given-names></name><name><surname>Scotte</surname><given-names>M</given-names></name><name><surname>Daveau</surname><given-names>M</given-names></name><etal/></person-group><year>2001</year><article-title>Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes.</article-title><source>Inflamm Res.</source><volume>50</volume><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">11556518</pub-id></citation></ref><ref id="pone.0001765-Hara1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>K</given-names></name><name><surname>Horikoshi</surname><given-names>M</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Yago</surname><given-names>H</given-names></name><name><surname>Miyazaki</surname><given-names>O</given-names></name></person-group><year>2006</year><article-title>Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome.</article-title><source>Diabetes Care</source><volume>29</volume><fpage>1357</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">16732021</pub-id></citation></ref><ref id="pone.0001765-Fisher1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>FF</given-names></name><name><surname>Trujillo</surname><given-names>ME</given-names></name><name><surname>Hanif</surname><given-names>W</given-names></name><name><surname>Barnett</surname><given-names>AH</given-names></name><name><surname>McTernan</surname><given-names>PG</given-names></name><etal/></person-group><year>2005</year><article-title>Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males.</article-title><source>Diabetologia</source><volume>48</volume><fpage>1084</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">15902402</pub-id></citation></ref><ref id="pone.0001765-LaraCastro1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lara-Castro</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>N</given-names></name><name><surname>Wallace</surname><given-names>P</given-names></name><name><surname>Klein</surname><given-names>RL</given-names></name><name><surname>Garvey</surname><given-names>WT</given-names></name></person-group><year>2006</year><article-title>Adiponectin multimeric complexes and the metabolic syndrome trait cluster.</article-title><source>Diabetes</source><volume>55</volume><fpage>249</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">16380500</pub-id></citation></ref><ref id="pone.0001765-Fasshauer1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fasshauer</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>J</given-names></name><name><surname>Neumann</surname><given-names>S</given-names></name><name><surname>Eszlinger</surname><given-names>M</given-names></name><name><surname>Paschke</surname><given-names>R</given-names></name></person-group><year>2002</year><article-title>Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes.</article-title><source>Biochem Biophys Res Commun</source><volume>290</volume><fpage>1084</fpage><lpage>1089</lpage><pub-id pub-id-type="pmid">11798186</pub-id></citation></ref><ref id="pone.0001765-Kappes1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kappes</surname><given-names>A</given-names></name><name><surname>Loffler</surname><given-names>G</given-names></name></person-group><year>2000</year><article-title>Influences of ionomycin, dibutyryl-cycloAMP and tumour necrosis factor-alpha on intracellular amount and secretion of apM1 in differentiating primary human preadipocytes.</article-title><source>Horm Metab Res</source><volume>32</volume><fpage>548</fpage><lpage>554</lpage><pub-id pub-id-type="pmid">11246823</pub-id></citation></ref><ref id="pone.0001765-Bruun1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bruun</surname><given-names>JM</given-names></name><name><surname>Lihn</surname><given-names>AS</given-names></name><name><surname>Verdich</surname><given-names>C</given-names></name><name><surname>Pedersen</surname><given-names>SB</given-names></name><name><surname>Toubro</surname><given-names>S</given-names></name><etal/></person-group><year>2003</year><article-title>Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans.</article-title><source>Am J Physiol Endocrinol Metab</source><volume>285</volume><fpage>E527</fpage><lpage>E533</lpage><pub-id pub-id-type="pmid">12736161</pub-id></citation></ref><ref id="pone.0001765-Lihn1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lihn</surname><given-names>AS</given-names></name><name><surname>Richelsen</surname><given-names>B</given-names></name><name><surname>Pedersen</surname><given-names>SB</given-names></name><name><surname>Haugaard</surname><given-names>SB</given-names></name><name><surname>Rathje</surname><given-names>GS</given-names></name><etal/></person-group><year>2003</year><article-title>Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels.</article-title><source>Am J Physiol Endocrinol Metab</source><volume>285</volume><fpage>E1072</fpage><lpage>E1080</lpage><pub-id pub-id-type="pmid">12876073</pub-id></citation></ref><ref id="pone.0001765-Fasshauer2"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fasshauer</surname><given-names>M</given-names></name><name><surname>Kralisch</surname><given-names>S</given-names></name><name><surname>Klier</surname><given-names>M</given-names></name><name><surname>Lossner</surname><given-names>U</given-names></name><name><surname>Bluher</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes.</article-title><source>Biochem Biophys Res Commun</source><volume>301</volume><fpage>1045</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">12589818</pub-id></citation></ref><ref id="pone.0001765-Sopasakis1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sopasakis</surname><given-names>VR</given-names></name><name><surname>Sandqvist</surname><given-names>M</given-names></name><name><surname>Gustafson</surname><given-names>B</given-names></name><name><surname>Hammarstedt</surname><given-names>A</given-names></name><name><surname>Schmelz</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator.</article-title><source>Obes Res</source><volume>12</volume><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">15044662</pub-id></citation></ref><ref id="pone.0001765-Roden1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roden</surname><given-names>M</given-names></name></person-group><year>2006</year><article-title>Mechanisms of Disease: hepatic steatosis in type 2 diabetes&#x02013;pathogenesis and clinical relevance.</article-title><source>Nat Clin Pract Endocrinol Metab</source><volume>2</volume><fpage>335</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">16932311</pub-id></citation></ref><ref id="pone.0001765-Lin1"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Braymer</surname><given-names>HD</given-names></name><name><surname>Bray</surname><given-names>GA</given-names></name><name><surname>York</surname><given-names>DA</given-names></name></person-group><year>1998</year><article-title>Differential expression of insulin receptor tyrosine kinase inhibitor (fetuin) gene in a model of diet-induced obesity.</article-title><source>Life Sci</source><volume>63</volume><fpage>145</fpage><lpage>153</lpage><pub-id pub-id-type="pmid">9674949</pub-id></citation></ref><ref id="pone.0001765-Chan1"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Barrett</surname><given-names>HP</given-names></name><name><surname>Watts</surname><given-names>GF</given-names></name></person-group><year>2004</year><article-title>Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.</article-title><source>Am J Cardiovasc Drugs</source><volume>4</volume><fpage>227</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">15285698</pub-id></citation></ref><ref id="pone.0001765-Lam1"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>KS</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>Adiponectin: protection of the endothelium.</article-title><source>Curr Diab Rep</source><volume>5</volume><fpage>254</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">16033674</pub-id></citation></ref><ref id="pone.0001765-Santoliquido1"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santoliquido</surname><given-names>A</given-names></name><name><surname>Di Campli</surname><given-names>C</given-names></name><name><surname>Miele</surname><given-names>L</given-names></name><name><surname>Gabrieli</surname><given-names>ML</given-names></name><name><surname>Forgione</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Hepatic steatosis and vascular disease.</article-title><source>Eur Rev Med Pharmacol Sci</source><volume>9</volume><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">16231588</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>The study was partially supported grants from the Deutsche Forschungsgemeinschaft(KFO 114 and HE 3653/3-1) and the European Community's frame program FP6 EUGENE2 (LSHM-CT-2004-512013). The funders had a limited influence on the design of the study but no influence on the conduct of the study, on the collection, analysis, and interpretation of the data, and on the preparation, review, or approval of the manuscript.</p></fn></fn-group></back></article> 